Sight Sciences Q2 FY26 net loss narrows 63% to $4.4 million; revenue rises 20% to $23.4 million
SGHT•Full-year outlook raised
Raised full-year revenue guidance to $88 million-$92 million; cut non-GAAP adjusted operating expense outlook to $92 million-$94 million.
Margins, cash use and expenses
Gross margin rose 6.6 percentage points to 91% on a $1.4 million tariff-refund benefit; cash used totaled $5.2 million, including a $5.4 million litigation success fee.
Cash and cash equivalents ended June at $79.8 million; total operating expenses fell 11% to $25.3 million.
Q2 revenue rises and loss narrows
Sight Sciences posted Q2 revenue of $23.4 million, up 20% year over year; net loss narrowed to $4.4 million, or $0.08 a share.
Interventional Glaucoma revenue rose 8% to on higher volumes; Interventional Dry Eye revenue climbed to from .
